BRPI0619255A8 - Composto de peptídeo, composição farmacêutica, uso do composto e medicamento para imunoterapia de câncer - Google Patents

Composto de peptídeo, composição farmacêutica, uso do composto e medicamento para imunoterapia de câncer

Info

Publication number
BRPI0619255A8
BRPI0619255A8 BRPI0619255A BRPI0619255A BRPI0619255A8 BR PI0619255 A8 BRPI0619255 A8 BR PI0619255A8 BR PI0619255 A BRPI0619255 A BR PI0619255A BR PI0619255 A BRPI0619255 A BR PI0619255A BR PI0619255 A8 BRPI0619255 A8 BR PI0619255A8
Authority
BR
Brazil
Prior art keywords
compound
cancer immunotherapy
pharmaceutical composition
hydrogen atom
drug
Prior art date
Application number
BRPI0619255A
Other languages
English (en)
Inventor
Nishihara Toshio
Gotoh Masashi
Original Assignee
Int Inst Cancer Immunology Inc
Dainippon Sumitomo Pharma Co
Chugai Seiyaku Kabishiki Kaisha
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Int Inst Cancer Immunology Inc, Dainippon Sumitomo Pharma Co, Chugai Seiyaku Kabishiki Kaisha, Sumitomo Dainippon Pharma Co Ltd filed Critical Int Inst Cancer Immunology Inc
Publication of BRPI0619255A2 publication Critical patent/BRPI0619255A2/pt
Publication of BRPI0619255A8 publication Critical patent/BRPI0619255A8/pt
Publication of BRPI0619255B1 publication Critical patent/BRPI0619255B1/pt
Publication of BRPI0619255B8 publication Critical patent/BRPI0619255B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production

Abstract

COMPOSTO DE PEPTÍDEO, COMPOSIÇÃO FARMACÊUTICA, ANTICORPO, USO DO COMPOSTO E MEDICAMENTO PARA IMUNOTERAPIA DE CÂNCER. A presente invenção refere-se a um composto da fórmula (1) em que X é um resíduo de tirosina ou um resíduo de metionina; Y e Z são, cada, uma ligação simples ou similar; R1 é um átomo de hidrogênio ou similar; R2 é um grupo hidróxi ou similar; R3 é um átomo de hidrogênio, grupo alquila, grupo amino ou similar; R4 é um átomo de hidrogênio, grupo alquila, grupo carbóxi ou similar; m é 1 ou 2; e n é um número inteiro de 0 a 2, com a condição de que quando n é 0, R3 é um átomo de hidrogênio ou um grupo alquila, ou um sal farmaceuticamente aceitável do mesmo, e seu uso em imunoterapia de câncer.
BRPI0619255A 2005-11-30 2006-11-29 composto de peptídeo, composição farmacêutica, uso do composto e medicamento para imunoterapia de câncer BRPI0619255B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005346577 2005-11-30
JP2005-346577 2005-11-30
PCT/JP2006/323827 WO2007063903A1 (ja) 2005-11-30 2006-11-29 新規ペプチド化合物

Publications (4)

Publication Number Publication Date
BRPI0619255A2 BRPI0619255A2 (pt) 2011-09-27
BRPI0619255A8 true BRPI0619255A8 (pt) 2015-12-15
BRPI0619255B1 BRPI0619255B1 (pt) 2021-05-11
BRPI0619255B8 BRPI0619255B8 (pt) 2021-05-25

Family

ID=38092236

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0619255A BRPI0619255B8 (pt) 2005-11-30 2006-11-29 composto de peptídeo, composição farmacêutica, uso do composto e medicamento para imunoterapia de câncer

Country Status (18)

Country Link
US (4) US7939627B2 (pt)
EP (1) EP1961761B1 (pt)
JP (4) JP4394724B2 (pt)
KR (1) KR101385805B1 (pt)
CN (2) CN101336249A (pt)
AU (1) AU2006319892B2 (pt)
BR (1) BRPI0619255B8 (pt)
CA (1) CA2631292C (pt)
DE (1) DE602006017880D1 (pt)
DK (1) DK1961761T3 (pt)
ES (1) ES2352855T3 (pt)
HK (2) HK1122819A1 (pt)
PL (1) PL1961761T3 (pt)
PT (1) PT1961761E (pt)
RU (1) RU2424247C2 (pt)
SI (1) SI1961761T1 (pt)
TW (1) TWI372152B (pt)
WO (1) WO2007063903A1 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080070835A1 (en) 2003-11-05 2008-03-20 International Institute Of Cancer Immunology, Inc Hla-Dr-Binding Antigen Peptide Derived From Wt1
US8765687B2 (en) 2005-10-17 2014-07-01 Sloan Kettering Institute For Cancer Research WT1 HLA class II-binding peptides and compositions and methods comprising same
JP4394724B2 (ja) * 2005-11-30 2010-01-06 株式会社癌免疫研究所 新規ペプチド化合物
CA2645766A1 (en) 2006-04-10 2007-10-25 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
PT2119778E (pt) 2007-02-27 2016-02-15 Int Inst Cancer Immunology Inc Método para ativação de célula t auxiliar e composição para utilização no método
JP2011016751A (ja) * 2009-07-08 2011-01-27 Sumitomo Chemical Co Ltd 光学活性３−アミノピペリジン−１−カルボキシレート化合物の製造方法およびその製造方法に用いられる中間体
BR112012025044A2 (pt) 2010-03-31 2016-06-21 Stabilitech Ltd método para conservar adjuvantes de alum e vacinas com adjuvantes de alum
US20130164296A1 (en) 2010-03-31 2013-06-27 Jeffrey Drew Excipients for Stabilising Viral Particles, Polypeptides or Biological Material
CA2795013C (en) 2010-03-31 2018-10-16 Stabilitech Ltd. Stabilisation of viral particles
AR083295A1 (es) 2010-10-05 2013-02-13 Univ Osaka Metodo para activar celulas t auxiliares
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
US9539299B2 (en) * 2011-10-27 2017-01-10 International Institute Of Cancer Immunology, Inc. Combination therapy with WT1 peptide vaccine and temozolomide
EP3520810A3 (en) 2012-01-13 2019-11-06 Memorial Sloan-Kettering Cancer Center Immunogenic wt1 peptides and use thereof
WO2014007266A1 (ja) 2012-07-02 2014-01-09 大日本住友製薬株式会社 癌抗原ペプチド経皮剤
CN104853764B (zh) * 2012-12-13 2018-06-22 海德堡吕布莱希特-卡尔斯大学 用于预防和治疗癌症的msi-特异性移码肽(fsp)
WO2014098012A1 (ja) 2012-12-17 2014-06-26 大塚製薬株式会社 ヘルパーt細胞の活性化方法
US9919037B2 (en) * 2013-01-15 2018-03-20 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
RU2687144C2 (ru) 2013-02-05 2019-05-07 Нитто Денко Корпорейшн Композиция противораковой вакцины, содержащей пептид wt1, для трансдермального введения
US10195258B2 (en) 2013-02-05 2019-02-05 Nitto Denko Corporation Tape preparation of WT1 peptide cancer vaccine for transdermal administration
EP2762152A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation WT1 peptide cancer vaccine composition for transdermal administration
CN103961702B (zh) 2013-02-05 2019-04-09 日东电工株式会社 粘膜给予用wt1肽癌症疫苗组合物
WO2014136814A1 (ja) * 2013-03-08 2014-09-12 大鵬薬品工業株式会社 新規ｃｔｌエピトープ５連結ペプチド
ES2694328T3 (es) 2013-03-12 2018-12-19 Sumitomo Dainippon Pharma Co., Ltd. Composición acuosa líquida
WO2014157704A1 (ja) * 2013-03-29 2014-10-02 大日本住友製薬株式会社 Ｅｒａｐ１によるトリミング機能をきっかけとしたコンジュゲートワクチン
MY171854A (en) 2013-03-29 2019-11-05 Sumitomo Dainippon Pharma Co Ltd Wt1 antigen peptide conjugate vaccine
WO2015060235A1 (ja) 2013-10-21 2015-04-30 大鵬薬品工業株式会社 新規ｃｔｌエピトープ４連結ペプチド
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
US10471136B2 (en) 2014-09-27 2019-11-12 Sumitomo Dainippon Pharma Co., Ltd. Pharmaceutical composition for injection
JP6671141B2 (ja) * 2014-10-21 2020-03-25 大日本住友製薬株式会社 懸濁液剤
JP6699013B2 (ja) * 2014-12-25 2020-05-27 国立大学法人三重大学 Ｗｔ１由来ペプチド認識抗体
JP7209963B2 (ja) * 2016-11-30 2023-01-23 住友ファーマ株式会社 Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ
EP3604325A4 (en) 2017-03-30 2021-01-13 Sumitomo Dainippon Pharma Co., Ltd. WT1 CANCER ANTIGEN PEPTIDE AND PEPTIDE CONJUGATE BODY WITH IT
GB2562241B (en) 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
US20210338587A1 (en) 2018-09-28 2021-11-04 Sumitomo Dainippon Pharma Co., Ltd. Injectable composition
KR20210073540A (ko) 2018-10-05 2021-06-18 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 양성 종양의 예방 또는 치료약
CN113412271A (zh) * 2019-02-13 2021-09-17 大日本住友制药株式会社 具有半胱氨酸残基的哈米特林衍生物
AU2020255935A1 (en) 2019-04-05 2021-12-02 Sumitomo Pharma Co., Ltd. Water soluble adjuvant and composition containing same
KR20220004637A (ko) 2019-04-05 2022-01-11 다이닛본 스미토모 세이야꾸 가부시끼가이샤 수용성 보조제
KR20230009426A (ko) 2020-05-12 2023-01-17 스미토모 파마 가부시키가이샤 암을 처치하기 위한 의약 조성물
AU2022327884A1 (en) 2021-08-12 2024-02-22 International Institute Of Cancer Immunology, Inc. Pharmaceutical composition and method for treatment or prevention of cancer

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858358A (en) * 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6297041B1 (en) * 1992-03-11 2001-10-02 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US6309642B1 (en) * 1997-04-28 2001-10-30 The Research And Development Institute, Inc. Peptides which mimic candida carbohydrate epitopes and their use in a vaccine
US5858682A (en) * 1996-08-02 1999-01-12 Pharmingen E2A/pbx1 fusion protein specific monoclonal antibodies
AU4932199A (en) * 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
MXPA01003344A (es) 1998-09-30 2004-04-21 Corixa Corp Composiciones y metodos para inmunoterapia especifica de wt1.
GB9823897D0 (en) 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
US7534605B2 (en) * 1999-06-08 2009-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
US20040097703A1 (en) 2001-03-22 2004-05-20 Haruo Sugiyama Wt1 modified peptide
DE60235155D1 (de) * 2001-04-17 2010-03-11 Childrens Hosp Oak Res Inst Monoklonale antikörper gegen molekulare mimetika von meningokokken-b-epitopen
US20050002951A1 (en) * 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
US8735357B2 (en) * 2001-09-28 2014-05-27 International Institute Of Cancer Immunology, Inc. Method of inducing antigen-specific T cells
WO2003106682A1 (ja) * 2002-06-12 2003-12-24 中外製薬株式会社 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
US7342092B2 (en) * 2002-09-12 2008-03-11 International Institute Of Cancer Immunology, Inc. Cancer antigen peptide formulations
DE60329201D1 (de) * 2002-09-20 2009-10-22 Chugai Pharmaceutical Co Ltd Substituierte wt1-peptide
CN1735864A (zh) * 2003-01-13 2006-02-15 施克莱无线公司 主机可扩展无线应用接口
KR20120054644A (ko) * 2003-01-15 2012-05-30 추가이 세이야쿠 가부시키가이샤 이량체화 펩티드
EP2343083B1 (en) * 2003-06-27 2014-01-15 International Institute of Cancer Immunology, Inc. Method of diagnosing cancer comprising the measurement of WT1-specific CTL precursor cells
US20080070835A1 (en) * 2003-11-05 2008-03-20 International Institute Of Cancer Immunology, Inc Hla-Dr-Binding Antigen Peptide Derived From Wt1
EP1703887A4 (en) * 2003-12-31 2009-10-21 Univ Rochester IMMUNOGENIC POLYPEPTIDES AND CONJUGATES THAT CAN INDUCE ANTIBODIES AGAINST PATHOGENIC AGENTS AND USES THEREOF
DK1731605T3 (da) 2004-03-31 2010-05-25 Int Inst Cancer Immunology Inc Cancerantigenpeptider der er afledt af WT1
WO2005121178A2 (en) * 2004-06-08 2005-12-22 Wisconsin Alumni Research Foundation Immunoaffinity chromatography polyol-responsive monoclonal antibodies
JP4394724B2 (ja) * 2005-11-30 2010-01-06 株式会社癌免疫研究所 新規ペプチド化合物

Also Published As

Publication number Publication date
PL1961761T3 (pl) 2011-04-29
EP1961761A1 (en) 2008-08-27
ES2352855T3 (es) 2011-02-23
KR20080073356A (ko) 2008-08-08
US7939627B2 (en) 2011-05-10
US20140046036A1 (en) 2014-02-13
AU2006319892A1 (en) 2007-06-07
PT1961761E (pt) 2010-12-16
KR101385805B1 (ko) 2014-04-16
CA2631292C (en) 2014-05-06
US20100062010A1 (en) 2010-03-11
US9273148B2 (en) 2016-03-01
JP5800928B2 (ja) 2015-10-28
HK1221230A1 (zh) 2017-05-26
DK1961761T3 (da) 2010-11-29
HK1122819A1 (en) 2009-05-29
US9765114B2 (en) 2017-09-19
BRPI0619255B1 (pt) 2021-05-11
EP1961761A4 (en) 2009-01-21
US20160168197A1 (en) 2016-06-16
WO2007063903A1 (ja) 2007-06-07
JPWO2007063903A1 (ja) 2009-05-07
RU2008126305A (ru) 2010-01-10
EP1961761B1 (en) 2010-10-27
BRPI0619255A2 (pt) 2011-09-27
BRPI0619255B8 (pt) 2021-05-25
SI1961761T1 (sl) 2010-12-31
JP5049323B2 (ja) 2012-10-17
AU2006319892B2 (en) 2012-05-10
RU2424247C2 (ru) 2011-07-20
TW200730540A (en) 2007-08-16
JP2014080435A (ja) 2014-05-08
CN101336249A (zh) 2008-12-31
JP5597668B2 (ja) 2014-10-01
JP2009286792A (ja) 2009-12-10
DE602006017880D1 (pt) 2010-12-09
TWI372152B (en) 2012-09-11
CN105315347A (zh) 2016-02-10
US8575308B2 (en) 2013-11-05
CA2631292A1 (en) 2007-06-07
JP4394724B2 (ja) 2010-01-06
JP2012158597A (ja) 2012-08-23
US20110229506A1 (en) 2011-09-22

Similar Documents

Publication Publication Date Title
BRPI0619255A8 (pt) Composto de peptídeo, composição farmacêutica, uso do composto e medicamento para imunoterapia de câncer
BRPI0417947A (pt) composto, composição farmacêutica, fabricação de um medicamento para o uso no tratamento e/ou prevenção de um metabólico distúrbio, e, formulação farmacêutica
BR112018068278A2 (pt) derivado de 3-desóxi e suas composições farmacêuticas
BR0314113A (pt) Derivados de amino propanol
BRPI0813244B8 (pt) compostos derivados de pirazinona, composições compreendendo ditos compostos, uso dos compostos no tratamento de doenças de pulmão e composto intermediário
BRPI0714885B8 (pt) compostos terapêuticos e seu uso
BRPI0507903A (pt) derivados de quinazolina e composição farmacêutica compreendendo os mesmos
BRPI0407810A (pt) composto, composição farmacêutica, ativador da glicocinase, e, medicamento
ECSP067110A (es) Derivados de 2-carbamida-4-feniltiazol, su preparación y su aplicación en terapéutica
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
BRPI0614524B8 (pt) uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto, e o referido composto
TW200738658A (en) Novel compounds
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
TW200801035A (en) Peptide vaccine for producing anti-amyloid beta peptide antibody
AR054129A1 (es) Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7
GEP20104882B (en) Age inhibitors
TW200640863A (en) Compounds which potentiate glutamate receptor and uses thereof in medicine
BRPI0511999A (pt) compostos como antagonistas de ccr5
BRPI0620985B1 (pt) composição farmacêutica, e usos de derivados de triazina e sensibilizadores de insulina
BRPI0418474A (pt) solução aquosa parenteral estável
BR0212353A (pt) Composto, composição farmacêutica, e, uso de um composto
UY30356A1 (es) Derivados de 3-halo-n-(2.(4-fluorofenil)-4-oxobutil)-n-metil-5-(trifluorometil)benzamida y composiciones de los mismos.
BR112012009311A2 (pt) composto, composição farmacêutica, e, uso do composto
BRPI0408918A (pt) formulação parenteral de ácido micofenólico, um sal ou pró-droga do mesmo
BRPI0519764A2 (pt) composiÇÕes farmacÊuticas derivadas de Ácido xanturÊnico e mÉtodos relacionados a estas

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.

B25A Requested transfer of rights approved

Owner name: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) , SUMITOMO DAINIPPON PHARMA CO., LTD. (JP)

Owner name: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07K 7/06 (2006.01), A61K 39/00 (2006.01), C07K 14

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/11/2006, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/11/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25D Requested change of name of applicant approved

Owner name: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) ; SUMITOMO PHARMA CO., LTD. (JP)

B25G Requested change of headquarter approved

Owner name: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) ; SUMITOMO PHARMA CO., LTD. (JP)